A case of idiopathic follicular mucinosis treated with bexarotene gel

Heyl, Jennifer; Mehregan, Darius; Kado, Jessica; Campbell, Michelle

doi:10.1111/j.1365-4632.2012.05789.x

Cited by 11 publications

(6 citation statements)

References 15 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Idiopathic FM treatments include topical and systemic retinoids, benzoyl peroxide, topical steroids, oral dapsone, antimalarials, tetracyclines, and minocycline. 5 Our patient failed to improve with F I G U R E 1 Clinical photos of the facial skin. A, Skin-colored acneiform FM papules on the cheeks and chin at presentation.…”

Section: Discussionmentioning

confidence: 83%

“…New facial FM lesions developed infrequently for the next 2 years, but each cleared within 2-6 weeks when twice weekly nbUVB was restarted (Figure 1C). Discontinuation of oral dapsone did not impact the frequency of new lesions nor nbUVB treatment response.DISCUSSIONIdiopathic FM treatments include topical and systemic retinoids, benzoyl peroxide, topical steroids, oral dapsone, antimalarials, tetracyclines, and minocycline 5. Our patient failed to improve with F I G U R E 1 Clinical photos of the facial skin.…”

mentioning

confidence: 79%

See 1 more Smart Citation

Acneiform follicular mucinosis successfully treated with lesional narrowband UVB, oral dapsone, and topical retinoid therapy

Gupta

Castro

Diwan

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 83%

mentioning

confidence: 79%

Acneiform follicular mucinosis successfully treated with lesional narrowband UVB, oral dapsone, and topical retinoid therapy

Gupta

Castro

Diwan

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

“…There has also been an isolated clinical case of treatment of CTCLs with HCQ [ 118 ], while it is also known that several case reports use the same substance to treat diverse forms of follicular mucinosiss [ 119 , 120 ].…”

Section: The Developed and Under-investigation Treatments To Address ...mentioning

confidence: 99%

A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments

Zengarini,

Guglielmo,

Mussi

et al. 2024

Antibodies

View full text Add to dashboard Cite

The CCR4 receptor is a pivotal target in cutaneous T-cell lymphoma (CTCL) therapy due to its role in impairing immune responses against malignant T-cells and expression profiles. Monoclonal antibodies like mogamulizumab effectively bind to CCR4, reducing tumour burden and enhancing patient outcomes by inhibiting the receptor’s interaction with ligands, thereby hindering malignant T-cell migration and survival. Combining CCR4 antibodies with chemotherapy, radiation, and other drugs is being explored for synergistic effects. Additionally, small-molecular inhibitors, old pharmacological agents interacting with CCR4, and CAR-T therapies are under investigation. Challenges include drug resistance, off-target effects, and patient selection, addressed through ongoing trials refining protocols and identifying biomarkers. Despite advancements, real-life data for most of the emerging treatments are needed to temper expectations. In conclusion, CCR4-targeted therapies show promise for CTCL management, but challenges persist. Continued research aims to optimise treatments, enhance outcomes, and transform CTCL management. This review aims to elucidate the biological rationale and the several agents under various stages of development and clinical evaluation with the actual known data.

show abstract

“…18 The other (1/7) was treated with topical bexarotene 1% gel. 19 Notably, the patient treated with bexarotene gel only had a 1-month history of hair loss. 19 Hair regrowth in all other patients began at 6 weeks and had complete regrowth between 2 and 6.5 months.…”

Section: Fmmentioning

confidence: 99%

Hair regrowth in cicatricial alopecia: A literature review

Poliner

Tosti

2021

The Journal of Dermatology

View full text Add to dashboard Cite

Cicatricial alopecias (CA) is a term for a group of subtypes of hair loss in which the hair follicle is destroyed by an unknown inflammatory mechanism. 1,2 Clinically, CA results in loss of the follicular ostia. 1,3 There are three main groups of CA that are grouped based on the perifollicular inflammatory response: primary neutrophilic, primary lymphocytic, or mixed subtypes. 2 Table 1 displays the inflammatory category in which each subtype belongs. The goal of treatment is to stop the ongoing inflammation through a combination of topical or intralesional corticosteroids, antimalarials, immunosuppressants, and antimicrobials, although a number of other medications, lasers, and other therapies have been trialed in refractory cases. 4 Alopecia can have profound psychosocial ramifications and negatively affect a patient's quality of life and self-esteem. 5,6 Even with treatment, patients usually do not experience hair regrowth. 4 Thus, it is important to counsel patients that the goal of treatment is to stop the ongoing inflammation and prevent further hair loss. This conversation must be undertaken delicately as this can be an incredibly difficult conversion for the patient. However, there have been reports in the literature of hair regrowth following treatment of CA. Thus, the aim of this review is to describe the cases of hair regrowth in CA in the published literature. | ME THODSA primary literature search was completed in August 2020 using the keywords "regrowth", "growth", and "name of each subtype of cicatricial alopecia" (e.g., "frontal fibrosing alopecia" or "lichen planopilaris").The databases searched included: PubMed, Cochrane, and Google Scholar. The subtypes of CA that were included in this search were: lichen planopilaris (LPP), frontal fibrosing alopecia (FFA), Graham-Little Syndrome (GLS), central centrifugal CA (CCCA), discoid lupus erythematous (DLE), follicular mucinosis (FM), keratosis follicularis spinulosa decalvans (KFSD), pseudopelade of Brocq, dissecting cellulitis of the scalp (DCS), folliculitis decalvans (FD), acne keloidalis (AK), acne necrotica (AN), and erosive pustular dermatosis of the scalp (EPDS).Eligibility was determined upon review of the article to determine whether they reported documented, either written or photographed, report of hair regrowth. References from each study were assessed to determine if any fit inclusion criteria. Only studies published in English were included.

show abstract

A case of idiopathic follicular mucinosis treated with bexarotene gel

Abstract: Background Topical bexarotene 1% gel is currently FDA-approved for early stage (IA and

Cited by 11 publications

References 15 publications

Acneiform follicular mucinosis successfully treated with lesional narrowband UVB, oral dapsone, and topical retinoid therapy

Acneiform follicular mucinosis successfully treated with lesional narrowband UVB, oral dapsone, and topical retinoid therapy

A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments

Hair regrowth in cicatricial alopecia: A literature review

Contact Info

Product

Resources

About